Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).
Sehhoon ParkRichard BaldryHyun Ae JungJong-Mu SunSe-Hoon LeeJin Seok AhnYu Jung KimYoung Joo LeeDong Wan KimSang-We KimKi Hyeong LeeWon Jae LeeJung Won ChoiKyuha ChongJung-Il LeeSo-Hyeon GwonNak-Hoon SonMyung-Ju AhnPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
The study demonstrates significant intracranial efficacy and survival benefits of 80 mg once daily osimertinib in NSCLC patients with LMs. The data support considering daily 80 mg of osimertinib as a treatment option for EGFR-mutated NSCLC patients with LMs, irrespective of T790M mutation status.
Keyphrases